INTERVENTION 1:	Intervention	0
Arm I Zoledronate	Intervention	1
Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.	Intervention	2
month	UO:0000035	55-60
month	UO:0000035	67-72
month	UO:0000035	96-101
zoledronic acid: Given IV	Intervention	3
zoledronic acid	CHEBI:46557	0-15
INTERVENTION 2:	Intervention	4
Arm II Clodronate	Intervention	5
Patients receive oral clodronate once daily for 35 months.	Intervention	6
clodronate disodium: Given orally	Intervention	7
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed primary adenocarcinoma of the breast	Eligibility	1
adenocarcinoma	DOID:299	33-47
breast	UBERON:0000310	55-61
Stage I-III disease	Eligibility	2
disease	DOID:4,OGMS:0000031	12-19
No evidence of metastatic disease	Eligibility	3
disease	DOID:4,OGMS:0000031	26-33
Must have undergone lumpectomy or total mastectomy for primary disease within the past 12 weeks, or have completed chemotherapy within the past 8 weeks	Eligibility	4
disease	DOID:4,OGMS:0000031	63-70
Axillary evaluation per institutional standards	Eligibility	5
Currently receiving or planning to receive standard adjuvant systemic therapy comprising chemotherapy, hormonal therapy, or combined chemotherapy/hormonal therapy for breast cancer	Eligibility	6
adjuvant	CHEBI:60809	52-60
breast cancer	DOID:1612	167-180
Patients who are at low risk for disease recurrence and for whom adjuvant systemic therapy will not be prescribed are not eligible	Eligibility	7
disease	DOID:4,OGMS:0000031	33-40
adjuvant	CHEBI:60809	65-73
Patients who receive biologic agents only or local radiotherapy only (without chemotherapy and/or hormone therapy) are not eligible	Eligibility	8
radiotherapy	OAE:0000235	51-63
hormone	CHEBI:24621	98-105
Additional therapies are allowed including radiotherapy and biologic agents (e.g., trastuzumab [Herceptin^Â®], bevacizumab, or hematopoietic growth factors)	Eligibility	9
radiotherapy	OAE:0000235	43-55
growth	GO:0040007	140-146
Neoadjuvant therapy or hormonal therapy alone is allowed provided study entry occurs  12 weeks after completion of surgery	Eligibility	10
surgery	OAE:0000067	115-122
Patients with skeletal pain are eligible provided bone scan and/or roentgenological exam are negative for metastatic disease	Eligibility	11
pain	HP:0012531	23-27
disease	DOID:4,OGMS:0000031	117-124
Suspicious findings must be confirmed as benign by x-ray, MRI, or biopsy	Eligibility	12
Hormone receptor status:	Eligibility	13
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	14
PATIENT CHARACTERISTICS:	Eligibility	15
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	16
age	PATO:0000011	0-3
18 and over	Eligibility	17
Sex	Eligibility	18
Female	Eligibility	19
female	PATO:0000383	0-6
Menopausal status	Eligibility	20
Not specified	Eligibility	21
Performance status	Eligibility	22
Zubrod 0-2	Eligibility	23
Life expectancy	Eligibility	24
Not specified	Eligibility	25
Hematopoietic	Eligibility	26
Not specified	Eligibility	27
Hepatic	Eligibility	28
Not specified	Eligibility	29
Renal	Eligibility	30
Creatinine  2 times upper limit of normal	Eligibility	31
creatinine	CHEBI:16737	0-10
Creatinine clearance  30 mL/min	Eligibility	32
creatinine clearance	CMO:0000765	0-20
No renal failure	Eligibility	33
Other	Eligibility	34
Not pregnant or nursing	Eligibility	35
Negative pregnancy test	Eligibility	36
Fertile patients must use effective contraception	Eligibility	37
No history of esophageal stricture or motility disorders	Eligibility	38
history	BFO:0000182	3-10
esophageal stricture	HP:0002043	14-34
Gastroesophageal reflux disorder allowed	Eligibility	39
gastroesophageal reflux	HP:0002020	0-23
disorder	OGMS:0000045	24-32
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission	Eligibility	40
skin cancer	DOID:4159	98-109
carcinoma	HP:0030731,DOID:305	111-120
cancer	DOID:162	103-109
cancer	DOID:162	180-186
PRIOR CONCURRENT THERAPY:	Eligibility	41
Biologic therapy	Eligibility	42
Prior or concurrent hematopoietic growth factors allowed	Eligibility	43
growth	GO:0040007	34-40
HER-2-targeted therapies allowed	Eligibility	44
Antiangiogenics allowed	Eligibility	45
Chemotherapy	Eligibility	46
See Disease Characteristics	Eligibility	47
disease	DOID:4,OGMS:0000031	4-11
Endocrine therapy	Eligibility	48
See Disease Characteristics	Eligibility	49
disease	DOID:4,OGMS:0000031	4-11
Radiotherapy	Eligibility	50
radiotherapy	OAE:0000235	0-12
Concurrent radiotherapy to the breast, chest wall, or lymph node group allowed at the discretion of the treating physician	Eligibility	51
radiotherapy	OAE:0000235	11-23
breast	UBERON:0000310	31-37
chest	UBERON:0001443	39-44
lymph	UBERON:0002391	54-59
group	CHEBI:24433	65-70
Surgery	Eligibility	52
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	53
disease	DOID:4,OGMS:0000031	4-11
Other	Eligibility	54
Prior neoadjuvant therapy allowed	Eligibility	55
Prior bisphosphonates for bone density allowed	Eligibility	56
No other concurrent bisphosphonates as adjuvant therapy or for treatment of osteoporosis	Eligibility	57
adjuvant	CHEBI:60809	39-47
osteoporosis	HP:0000939,DOID:11476	76-88
No concurrent enrollment in clinical trials with bone density as an endpoint	Eligibility	58
Concurrent enrollment on any other locoregional or systemic therapy breast cancer study (including cooperative group studies) allowed	Eligibility	59
breast cancer	DOID:1612	68-81
group	CHEBI:24433	111-116
Outcome Measurement:	Results	0
Disease-free Survival	Results	1
Time from date of registration to date of first observation of recurrence or death due to any cause. Patients last known to be alive who have not experienced recurrence of disease are censored at their last contact date. The outcome for the disease-free survival will be presented as 5 year survival rate.	Results	2
time	PATO:0000165	0-4
death	OAE:0000632	77-82
disease	DOID:4,OGMS:0000031	172-179
disease	DOID:4,OGMS:0000031	241-248
year	UO:0000036	286-290
rate	BAO:0080019	300-304
Time frame: Disease assessments are completed every 6 months for 5 years then annually for 5 years or until death or recurrence	Results	3
time	PATO:0000165	0-4
disease	DOID:4,OGMS:0000031	12-19
death	OAE:0000632	108-113
Results 1:	Results	4
Arm/Group Title: Arm I Zoledronate	Results	5
Arm/Group Description: Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.	Results	6
month	UO:0000035	78-83
month	UO:0000035	90-95
month	UO:0000035	119-124
zoledronic acid: Given IV	Results	7
zoledronic acid	CHEBI:46557	0-15
Overall Number of Participants Analyzed: 2231	Results	8
Measure Type: Number	Results	9
Unit of Measure: percentage of analyzed participants  88        (87 to 90)	Results	10
Results 2:	Results	11
Arm/Group Title: Arm II Clodronate	Results	12
Arm/Group Description: Patients receive oral clodronate once daily for 35 months.	Results	13
clodronate disodium: Given orally	Results	14
Overall Number of Participants Analyzed: 2235	Results	15
Measure Type: Number	Results	16
Unit of Measure: percentage of analyzed participants  88        (86 to 89)	Results	17
Adverse Events 1:	Adverse Events	0
Total: 21/2125 (0.99%)	Adverse Events	1
Febrile neutropenia 0/2125 (0.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Hemoglobin 0/2125 (0.00%)	Adverse Events	3
hemoglobin	CHEBI:35143	0-10
Cardiac General-Other 0/2125 (0.00%)	Adverse Events	4
Cardiac-ischemia/infarction 1/2125 (0.05%)	Adverse Events	5
Conduction abnorm/AV block - Sick sinus syndrome 0/2125 (0.00%)	Adverse Events	6
sick sinus syndrome	HP:0011704,DOID:13884	29-48
Left ventricular diastolic dysfunction 0/2125 (0.00%)	Adverse Events	7
left ventricular diastolic dysfunction	HP:0025168	0-38
Left ventricular systolic dysfunction 0/2125 (0.00%)	Adverse Events	8
left ventricular systolic dysfunction	HP:0025169	0-37
Pain - Cardiac/heart 0/2125 (0.00%)	Adverse Events	9
pain	HP:0012531	0-4
Adverse Events 2:	Adverse Events	10
Total: 190/2186 (8.69%)	Adverse Events	11
Febrile neutropenia 3/2186 (0.14%)	Adverse Events	12
neutropenia	HP:0001875,DOID:1227	8-19
Hemoglobin 3/2186 (0.14%)	Adverse Events	13
hemoglobin	CHEBI:35143	0-10
Cardiac General-Other 2/2186 (0.09%)	Adverse Events	14
Cardiac-ischemia/infarction 1/2186 (0.05%)	Adverse Events	15
Conduction abnorm/AV block - Sick sinus syndrome 1/2186 (0.05%)	Adverse Events	16
sick sinus syndrome	HP:0011704,DOID:13884	29-48
Left ventricular diastolic dysfunction 3/2186 (0.14%)	Adverse Events	17
left ventricular diastolic dysfunction	HP:0025168	0-38
Left ventricular systolic dysfunction 1/2186 (0.05%)	Adverse Events	18
left ventricular systolic dysfunction	HP:0025169	0-37
Pain - Cardiac/heart 3/2186 (0.14%)	Adverse Events	19
pain	HP:0012531	0-4
